Heraeus Medical licenses platform polymer technology to further its regenerative orthopedics strategy


Heraeus Medical GmbH (Hanau, Germany), a developer and manufacturer of biomaterials and medical products, has entered into an agreement with Locate Therapeutics (Nottingham, UK) to license intellectual property related to its TAOS (Targeted, Orchestrated Signaling) technology in orthopedic applications. TAOS is a proprietary polymer platform that can be applied to a number of medical applications. This agreement represents the first development program of the technology in this field and gives Heraeus Medical the rights to future co-developed orthopedic products as well as the processes involved in manufacturing the final product.

Locate is a privately owned University of Nottingham spin-out company, formerly known as RegenTec, that is specialized in regenerative medicine. The company's platform polymer technology, TAOS, is described as a world first in tissue repair. The material assembles itself following injection into a 3D porous structure, performing thereafter much like an implanted device. The ability to inject the material obviates the need for invasive surgery, and the material degrades naturally, leaving behind newly-formed tissue within the patient.

Read more